Antihypertensive effect of sacubitril/valsartan in peritoneal dialysis patients complicated with refractory hypertension

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043544

Enrollment

Unknown

Registered

2021-02-21

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory hypertension in maintenance peritoneal dialysis

Interventions

Case series:sacubitril/valsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The age is over 18 years old; 2. Regular peritoneal dialysis for more than 3 months; 3. Meet the diagnostic criteria of refractory hypertension; 4. Willing to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Take combined dialysis treatment; 2. Severe heart failure (NYHA grade IV); 3. People who are allergic to the active ingredients of sacubitril/valsartan (Sacubitril, Valsartan) or any auxiliary materials. 4. Acute complications (peritonitis, abdominal infection and other acute infections, etc.) occurred in recent 1 month; 5. Diagnosis of malignant tumor; 6. Patients with angioedema; 7. Mental disorders cannot cooperate; 8. It is impossible to measure blood pressure through upper limbs.

Design outcomes

Primary

Measure	Time frame
24 hour ambulatory blood pressure;	—

Countries

China

Contacts

Public ContactTianna

Department of Nephrology, General Hospital of Ningxia Medical University

snowwife@163.com18095173735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026